Clinical Presentation and Treatment of Childhood‐Onset Lupus Nephritis
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · 14.11.2023
DOI: 10.71749/pkj.12 ↗Kurz gefasst
Fachartikel in der Zeitschrift Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT), erschienen am 14.11.2023. Verfasst von Rita M Silva und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Lupus nephritis (LN) in childhood usually presents after the age of 10 years and is more common in female children. Despite the availability of effective immunosuppressive therapies, treatment response in childhood‐onset LN remains suboptimal, with 50% to 78% patients in full remission at 24 months. Improvement in survivals have also plateaued in past decades, and up to 9% and 14% of children with childhood‐onset LN died or developed end‐stage kidney disease during the course of illness, respectively. In our study, we aim to evaluate clinical presentation of LN with childhood‐onset, the treatment regimen instituted and the transition to adulthood.
Methods
Retrospective study of patients with LN followed by pediatric nephrology with subsequent transition to adult nephrology since 1995 to 2020.
Results
Fourteen patients (female:78.6%) with a median age of 26.3 ± 5.2 years (range 21‐44) were included. The median age of LN diagnosis was 13.6 years. The most common manifestation was proteinuria (71.4%). Of non‐renal manifestations, polyarthritis (100.0%) and rash (57.1%) were the most common. All patients underwent kidney biopsy with a majority of diffuse LN (class IV) (n=11, 78.6%). Induction therapy consisted of corticosteroids combined with other immunosuppressants, primarily cyclophosphamide (CYC) (n=5, 35.3%) or mycophenolate (MMF) (n=9, 64.7%). Maintenance therapy consisted of corticosteroids combined with primarily CYC (n=6, 42.9%) with posterior transition to MMF, or MMF (n=5, 35.7%) or azathioprine (n=3, 21.4%). A complete remission occurred in all patients. At the end of follow‐up, 11 patients (78.6%) were with MMF and oral corticosteroids and 3 patients were with oral corticosteroids. None of these patients developed end‐stage kidney disease or died.
Conclusion
The diagnosis of LN in pediatric age has its particularities and constitutes a challenge for the nephrology community. Biological therapy currently shows promise in improving the prognosis of these patients.
Schlagwörter
Zitieren
APA
Silva, R. M., Correia, A. L., Marques, M. G., Cordinhã, C., Romãozinho, C., Oliveira, N. A., Carmo, C. D., Gomes, C., Alves, & Rui (2023). Clinical Presentation and Treatment of Childhood‐Onset Lupus Nephritis. Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT). https://doi.org/10.71749/pkj.12
Vancouver
Silva RM, Correia AL, Marques MG, Cordinhã C, Romãozinho C, Oliveira NA, et al. Clinical Presentation and Treatment of Childhood‐Onset Lupus Nephritis. Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT). 2023. doi:10.71749/pkj.12
BibTeX
@article{Silva2023,
author = {Silva, Rita M and Correia, Ana Luísa and Marques, Maria Guedes and Cordinhã, Carolina and Romãozinho, Catarina and Oliveira, Nuno A and Carmo, Carmén do and Gomes, Clara and Alves and Rui},
title = {Clinical Presentation and Treatment of Childhood‐Onset Lupus Nephritis},
journal = {Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)},
year = {2023},
doi = {10.71749/pkj.12}
}
EUVIMED